Much of the conversation at THT revolved around how use of the device would be handled outside of specialized centers.

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

These early data are reassuring, but there are many questions yet to be explored in the upcoming pivotal trial, Nancy ...

While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...

Not everyone agrees: one expert says it would be more helpful to consider imaging as a quality measure at the local level.

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.

The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

The writing committee says collaborative efforts and patient-level perspective can improve management of pain in this ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

The recently approved device simplifies operator manipulations by loading a balloon and filter onto the stent.

Portable point-of-care blood tests, done by EMS before hospital arrival, need validation but could guide treatment and ...

Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...